Every Form 4 that Bioxytran Inc (BIXT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BIXT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIXT filings page.
Bioxytran, Inc. (BIXT) reported insider share purchases by director Alan Hoberman. On 08/12/2025, he acquired 10,417 shares of preferred stock at $0.485 per share, bringing his preferred holdings to 377,619 shares. On 11/14/2025, he bought an additional 38,588 preferred shares at $0.35 per share, increasing his total preferred holdings to 416,207 shares. On 11/18/2025, he purchased 210,000 shares of common stock at $0.60 per share and held 210,000 common shares afterward. All positions are reported as held directly by the insider.
Bioxytran, Inc. director reports preferred share purchases
A director of Bioxytran, Inc. (BIXT) filed a Form 4 disclosing open-market style acquisitions of the company’s preferred stock. On 08/12/2025, the reporting person acquired 10,417 preferred shares at a price of $0.485 per share. On 11/14/2025, the same person acquired an additional 38,588 preferred shares at a price of $0.35 per share.
After these transactions, the director beneficially owns 203,688 preferred shares, held directly. The filing does not list any derivative securities such as options or warrants, indicating the reported holdings are solely in the form of non-derivative preferred stock.
Bioxytran, Inc. (BIXT) reported insider purchases by a company director. On 08/12/2025, the director acquired 10,417 preferred shares at a price of $0.485 per share. On 11/14/2025, the same director acquired an additional 38,588 preferred shares at a price of $0.35 per share. Following these transactions, the director beneficially owned 379,177 preferred shares, held in direct ownership.
Bioxytran, Inc. (BIXT) reported an insider equity transaction by a director on a Form 4. On 11/14/2025, the director acquired 38,588 preferred shares at a price of $0.35 per share. Following this transaction, the director beneficially owned 372,580 shares, held as a direct ownership position. The filing was made by a single reporting person in the capacity of director, and no derivative securities transactions were reported.
Bioxytran, Inc. insider David Platt, who serves as CEO, director, and a 10% owner, reported changes in his indirect holdings of preferred stock on a Form 4/A. On 10/24/2024, 14,085,410 preferred shares held through NDPD Pharma were returned to treasury and cancelled. On the same date, 11,433,448 preferred shares were issued as payment for the sale of NDPD to Bioxytran, leaving Platt with 20,038,903 preferred shares beneficially owned indirectly through NDPD Pharma. The filing consolidates NDPD Pharma’s Bioxytran holdings under Platt’s indirect ownership.
Bioxytran, Inc. (BIXT) reported an amended insider transaction for Chief Commercial Officer and director Michael Sheikh. On 10/25/2024, he acquired 6,614,720 common shares of Bioxytran at a price of $0.545 per share, reported as an acquisition. After this transaction, he beneficially owned 8,214,720 shares, held directly. The filing explains that these shares were issued as payment for the sale of NDPD Pharma to Bioxytran, meaning the consideration for that business sale was paid in Bioxytran stock rather than cash.
Bioxytran, Inc. insider Ola Soderquist, who serves as CFO and is a 10% owner, reported multiple equity transactions dated 10/25/2024. He acquired 10,069,396 shares of preferred stock at $0.545 per share, bringing his beneficial ownership in that class to 13,976,456 preferred shares. He also acquired an additional 100,000 preferred shares at $0.005 per share, after which he held 13,876,456 preferred shares. In addition, he acquired 500,000 shares of common stock at $0.001 per share and held 500,000 common shares directly after the transaction. The filing states that some shares were issued as payment for the sale of NDPD Pharma to Bioxytran and that there was a 1:5 exchange of preferred stock into common stock.